QUALIFYING CONDITIONS
HIV/AIDS & Medical Marijuana: Pennsylvania & West Virginia Qualifying Condition Guide
CCC serves patients living with HIV/AIDS across Pennsylvania and West Virginia with compassionate, judgment-free evaluations. Our physicians are experienced in working alongside HIV and infectious disease specialists and can help ensure that any cannabis-based approach is considered within the full context of your antiretroviral regimen, including a review of potential drug interactions.
ABOUT HIV/AIDS
HIV (Human Immunodeficiency Virus) attacks the immune system, and if left untreated, can progress to AIDS (Acquired Immunodeficiency Syndrome), an advanced stage of infection in which the immune system is severely compromised. Pennsylvania and West Virginia both recognize HIV/AIDS as a qualifying condition for medical marijuana. If you or a loved one is living with HIV/AIDS, Compassionate Certification Centers can help you understand your options and determine whether certification may be appropriate as part of your care.
It is important to state clearly at the outset: Medical cannabis is not an antiretroviral therapy and does not treat, cure, or suppress HIV infection. Antiretroviral therapy (ART) is the only treatment proven to control HIV, prevent progression to AIDS, and reduce the risk of transmission to others. Where medical cannabis may have a role is in helping manage certain symptoms and treatment side effects, alongside not in place of ART. Cannabis should never be used to delay starting ART, or to justify stopping or reducing it.
What Is HIV/AIDS?
HIV attacks CD4 cells (a type of white blood cell essential to immune function), gradually weakening the body’s ability to fight off infections and certain cancers. Without treatment, HIV typically progresses over years to AIDS, the most advanced stage of the disease, marked by severe immune damage and susceptibility to opportunistic infections. With consistent antiretroviral therapy, most people with HIV today can achieve an undetectable viral load, maintain a healthy immune system, and live a normal lifespan. AIDS represents an advanced, largely preventable stage of the disease that occurs when HIV is left untreated, or treatment is not effective.
How Is HIV/AIDS Transmitted?
- Sexual contact with an infected person
- Sharing needles, syringes, or other injection drug equipment
- Blood transfusions or organ transplants (rare in the U.S. since routine screening began)
- Transmission from a mother to her child during pregnancy, childbirth, or breastfeeding
How Is HIV/AIDS Diagnosed?
HIV is diagnosed through blood or oral fluid tests that detect HIV antibodies, antigens, or both. A positive screening result is confirmed with a follow-up laboratory test, and ongoing viral load and CD4 cell count testing help determine disease stage and guide antiretroviral treatment. A diagnosis of AIDS is made when a person with HIV develops a CD4 count below 200 cells/mm³ or one of a defined list of opportunistic illnesses.
HIV/AIDS-Related Diagnoses That May Qualify in Pennsylvania and West Virginia
Pennsylvania and West Virginia’s medical marijuana programs recognize HIV/AIDS broadly, along with a range of related and overlapping diagnoses. Conditions that may qualify include:
- HIV/AIDS, primary diagnosis
- Acute HIV Infection
- Asymptomatic HIV Infection (Stage 1)
- Chronic HIV Infection (Stage 2)
- Acquired Immunodeficiency Syndrome (AIDS, Stage 3)
- HIV Wasting Syndrome
- HIV-Associated Neurocognitive Disorder (HAND)
- HIV-Associated Peripheral Neuropathy
- HIV/AIDS with Opportunistic Infection
Unsure whether your diagnosis or stage of HIV/AIDS qualifies? Our certified physicians can review your documentation and help determine eligibility.
Common Symptoms of HIV/AIDS
- Persistent fatigue
- Fever and night sweats
- Unintended weight loss and appetite loss
- Nausea and chronic diarrhea
- Sore throat and oral thrush (white patches in the mouth)
- Persistent dry cough
- Numbness, tingling, or pain in the hands or feet (peripheral neuropathy)
- Difficulty concentrating or other cognitive changes
- Abdominal pain
Medical Cannabis & HIV/AIDS: What the Research Currently Shows
HIV/AIDS is one of the qualifying conditions with the longest history of cannabis research, and an actual FDA-approved cannabinoid medication behind it. At the same time, it’s essential to separate cannabis’s role in symptom management from any claim about affecting the virus itself. This section presents that evidence honestly. It is informational only and does not constitute medical advice.
1. Appetite, Weight Loss & Wasting Syndrome: Where an FDA Approval Actually Exists
Dronabinol (Marinol), a synthetic form of THC, has been FDA-approved since the early 1990s specifically for anorexia associated with weight loss in patients with AIDS — one of only two indications (alongside chemotherapy-induced nausea and vomiting) for which any cannabinoid medication carries FDA approval. This approval is specific to a pharmaceutical formulation of THC, not to cannabis broadly. A series of small, placebo-controlled inpatient studies at Columbia University (Haney et al., 2005 and 2007) directly compared smoked marijuana and oral dronabinol in HIV-positive participants and found that both increased daily caloric intake in a dose-dependent way, with comparable tolerability, and without significant impairment on tasks measuring attention or memory. These were small, short-duration studies (10–30 participants over days, not months) and should be read as evidence of short-term tolerability and appetite effects, not long-term outcomes.
2. Neuropathic Pain: One of the Better-Studied Applications
HIV-associated peripheral neuropathy is a common and often difficult-to-treat complication of the disease. Two randomized, placebo-controlled clinical trials — Abrams et al. (2007, Neurology) and Ellis et al. (2009, Neuropsychopharmacology) — found that smoked cannabis reduced neuropathic pain more than placebo in HIV patients whose pain had not responded adequately to standard treatment. In the Ellis trial, cannabis reduced daily pain by 34% compared to 17% with placebo, and a larger share of cannabis users achieved at least 30% pain relief (52% vs. 24%). Both trials also reported cannabis-related side effects — including anxiety, sedation, disorientation, and dizziness — more frequently than placebo, and one participant in the Ellis trial withdrew due to a psychotic episode. These are genuine, well-designed randomized trials, but they are also small studies (28–55 participants) of short duration.
3. Cannabis Does Not Treat HIV Itself — What the Evidence Actually Shows on the Virus
Some early laboratory research has explored whether certain cannabinoids can influence immune cell activity or viral entry into cells in a test tube — findings that are sometimes cited to suggest cannabis has “antiviral” properties. This laboratory-level research has not been demonstrated in human clinical trials, and no reputable clinical guideline recommends cannabis as a way to suppress HIV or delay disease progression. Separately, a 2003 randomized, placebo-controlled trial (Abrams et al., Annals of Internal Medicine) found that short-term use (21 days) of smoked marijuana or oral dronabinol did not adversely affect HIV RNA viral load, CD4 or CD8 cell counts, or protease inhibitor drug levels in patients on antiretroviral therapy. This is reassuring short-term safety data — it is not evidence that cannabis treats or suppresses HIV. Antiretroviral therapy remains the only treatment proven to control the virus.
4. Drug Interactions With Antiretroviral Therapy
Cannabinoids and many antiretroviral medications are processed by the same liver enzyme pathway (cytochrome P450, particularly CYP3A4). Ritonavir- and cobicistat-boosted regimens, in particular, can increase cannabinoid blood levels and side effects, while cannabis use has been associated with reduced concentrations of certain antiretrovirals, such as atazanavir, in some patients. Patients on ART should disclose cannabis use to their HIV care team so potential interactions can be identified and monitored, particularly with protease-inhibitor- or booster-based regimens.
5. A Safety Consideration Specific to Immunocompromised Patients
Smoked or inhaled cannabis carries a documented, if uncommon, risk of fungal contamination — particularly Aspergillus mold — which can cause serious, even life-threatening lung infections in people with significantly weakened immune systems. This risk is low for people with well-controlled HIV and healthy immune function, but national guidance recommends that people with advanced immunosuppression (very low CD4 counts) avoid smoking cannabis and discuss other routes of administration with their HIV physician.
Medical Disclaimer: Medical cannabis is not an antiretroviral therapy and has not been shown to treat, cure, or suppress HIV infection. The only FDA-approved cannabinoid indication relevant to this condition is dronabinol for AIDS-related anorexia; no cannabis product is FDA-approved to treat HIV/AIDS itself or its complications more broadly. The information in this section is provided for general informational purposes only and does not constitute medical advice. Patients should never delay starting, reduce, or discontinue antiretroviral therapy based on cannabis use. Always consult your HIV care provider and a certified medical marijuana physician before incorporating cannabis into your care plan.
APPLICATION GUIDE
How to Get a Medical Marijuana Card for HIV/AIDS in Pennsylvania or West Virginia
Both Pennsylvania and West Virginia recognize HIV/AIDS as a qualifying condition. The certification process with CCC is straightforward:
Step 1: Register over the phone or online, next-day appointments are often available.
Step 2: Meet with a certified medical marijuana physician who will review your HIV/AIDS diagnosis, current antiretroviral regimen, and symptom profile to determine whether certification is appropriate.
Step 3: Receive your medical marijuana card and begin purchasing from licensed dispensaries in Pennsylvania or West Virginia.
SOURCES & REFERENCES
The following peer-reviewed publications and regulatory records informed the research summary above. All sources are publicly accessible via PubMed, PMC, or FDA.gov. No source should be interpreted as establishing medical cannabis as a treatment for HIV infection itself.
FDA Approval & Appetite / Wasting Syndrome Research
[1] U.S. Food and Drug Administration. Dronabinol (Marinol) drug approval — anorexia associated with weight loss in patients with AIDS.
Confirms dronabinol’s FDA-approved indication for AIDS-related anorexia, distinct from and not to be confused with approval of cannabis itself.
[2] Haney M, Rabkin J, Gunderson E, Foltin RW. (2005). “Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood.” Psychopharmacology, 181, 170–178.
A Columbia University inpatient study comparing dronabinol and smoked marijuana in HIV-positive participants, finding comparable increases in caloric intake with few adverse effects. Small sample, short duration.
[3] Haney M, Gunderson EW, Rabkin J, et al. (2007). “Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep.” Journal of Acquired Immune Deficiency Syndromes, 45(5), 545–554.
A follow-up 16-day inpatient study (n=10) finding both smoked marijuana and oral dronabinol dose-dependently increased caloric intake and body weight without significant cognitive impairment.
Neuropathic Pain & Safety Trials
[4] Abrams DI, Jay CA, Shade SB, et al. (2007). “Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.” Neurology, 68(7), 515–521.
A randomized, placebo-controlled trial (n=55) finding smoked cannabis reduced HIV-related neuropathic pain more than placebo, alongside a higher rate of side effects such as anxiety and sedation.
[5] Ellis RJ, Toperoff W, Vaida F, et al. (2009). “Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.” Neuropsychopharmacology, 34, 672–680.
A randomized crossover trial (n=28) confirming cannabis’s analgesic effect on HIV neuropathic pain; also reported treatment-limiting side effects in two participants, including one psychotic episode.
[6] Abrams DI, Hilton JF, Leiser RJ, et al. (2003). “Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.” Annals of Internal Medicine, 139(4), 258–266.
Found that 21 days of smoked marijuana or oral dronabinol did not adversely affect HIV RNA levels, CD4/CD8 cell counts, or protease inhibitor levels. Short-term safety data only — not evidence of antiviral benefit.
Drug Interactions & Immune Safety
[7] Ho C, et al. (2024). “Evaluation of potential drug–drug interactions with medical cannabis.” Clinical and Translational Science.
A review of documented cannabinoid interactions with CYP3A4-metabolized medications, including HIV protease inhibitors and pharmacokinetic boosters such as ritonavir and cobicistat.
[8] National Academies of Sciences, Engineering, and Medicine. (2017). “The Health Effects of Cannabis and Cannabinoids.” National Academies Press.
Consensus report noting the association between contaminated cannabis and Aspergillus infection risk, and recommending caution for immunocompromised patients considering smoked cannabis.
